Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 23, 2008

EyeCyte Obtains $3M from Pfizer through Series A Round

  • EyeCyte secured a $3 million series A financing through an agreement with Pfizer. The backing will reportedly support the company into 2010. EyeCyte focuses on stem/progenitor cell-based ophthalmology R&D.

    According to this investment, Pfizer will become EyeCyte’s sole pharmaceutical partner and have an advisory and board role. Pfizer will also have right of first refusal for a buy-out of EyeCyte or its technologies.

    “We are very pleased with the terms of our collaboration and believe that Pfizer shares our goal of building a premier ophthalmology research and development organization with an emphasis on stem/progenitor cell based therapies,” remarks Mohammad A. El-Kalay, Ph.D., president and CEO, EyeCyte.


Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »